About
Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
117
By Phase
PHASE1: 2PHASE1/PHASE2: 1
By Status
RECRUITING: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06450106Lead Sponsor
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
PHASE1Recruiting
18 participants
Started: May 8, 2025 · Completed: Mar 31, 2026
NCT06300411Lead Sponsor
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
PHASE1Recruiting
24 participants
Started: Jul 29, 2024 · Completed: Sep 30, 2025
NCT05710848Lead Sponsor
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
PHASE1/PHASE2Recruiting
75 participants
Started: Jul 11, 2023 · Completed: Dec 31, 2025
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...